	US 11,793,889 B2
	Methods for selective kinase inhibition by endogenously produced antagonists of one or more kinases
Bradley G Thompson, Calgary (CA)
Assigned to Kinase Pharma Inc., Calgary (CA)
Filed by Kinase Pharma Inc., Calgary (CA)
Filed on Sep. 24, 2018, as Appl. No. 16/139,835.
Prior Publication US 2020/0093940 A1, Mar. 26, 2020
Int. Cl. A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)

CPC A61K 48/0066 (2013.01) [A61K 48/0075 (2013.01); A61K 48/0083 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01)]

4 Claims

1. A method of treating one of cancer, autoimmune disease, and organ transplantation rejection, the method comprising a step of administering to a subject a therapeutically effective amount of an agent that downregulates a VEGF enzyme that is involved in regulation of phosphorylation, wherein the agent comprises a gene vector that comprises SEQ ID No. 1 and SEQ ID No. 2 for producing a regulatory molecule that downregulates the VEGF enzyme.